Micron Medical Hosting Key Opinion Leader Webinar on Protect PNS: A Percutaneous Wireless Micro-Neurostimulation Technology for Overactive Bladder December 9 at 11am EST

Tuesday, 01. December 2020 22:01

BOCA RATON, Fla., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Micron Medical (“Micron” or “the Company”), a privately-held medical device company engaged in the development, manufacture and pre-commercialization of innovative wireless, minimally invasive, electroceutical solutions for urological conditions, today announced that it will host a key opinion leader (KOL) webinar on its Protect PNS system for overactive bladder (OAB) on Wednesday, December 9, 2020, at 11:00 AM Eastern Time.

The webinar will feature a panel discussion with KOLs Larry Sirls, M.D., and Ken Peters, M.D. who will discuss the current treatment landscape and unmet medical need for patients with OAB, and Micron Medical's wireless percutaneous micro-neurostimulation technology, Protect PNS. Micron Medical’s CEO, Mark Landy, will also share insights on the Company’s commercial plans to introduce Protect PNS to the market. Protect PNS, pending receipt of FDA classification, is expected to be commercially available in the U.S. in 2021.

Protect PNS for OAB is an investigational device based on an innovative percutaneous wireless micro-neuromodulation technology and is implanted through a small introducer via a minimally invasive procedure. The pioneering solution includes a micro-sized integrated pulse generator and a 1 ounce external transmitter that is conveniently placed in clothing. Protect PNS provides therapy for the relief of OAB symptoms by delivering small controlled electrical pulses to the tibial nerve that travel to the sacral nerve plexus, the group of nerves near the pelvis that control bladder function.

To register for the event, please click here.

Larry Sirls, M.D. graduated from the University of Michigan Medical School and completed his urology residency at Henry Ford Hospital. He completed specialty fellowship training in Male and Female Pelvic Reconstructive Surgery, Urodynamics, Female Urology, and Neurourology at Kaiser Permanente Medical Center in Los Angeles. Dr. Sirls returned to Detroit in 1993 and has practiced at Beaumont Hospital Royal Oak since 1996. Dr. Sirls is the Director of Female Pelvic Medicine and Reconstructive Surgery at Beaumont Hospital Royal Oak, is a Professor at the Oakland University William Beaumont Medical School and is the Primary Investigator for the Beaumont Site of the National Institutes of Health Urinary Incontinence Treatment Network, one of only nine centers in the country selected to perform research on treatment options for urinary incontinence. His areas of interest include reconstructive urology, male and female incontinence and voiding difficulty. Dr. Sirls is widely published and is a national thought leader in the evaluation and treatment of male and female pelvic floor disorders. He travels to Sub-Saharan Africa yearly to perform complicated fistula and other reconstructive procedures.

Kenneth Peters, M.D., is Chair of Urology at Beaumont Health System in Royal Oak, Michigan, and Medical Director of the Beaumont Women’s Urology Center in Royal Oak, a unique multidisciplinary center dedicated to women with chronic pelvic pain and voiding dysfunction. Dr. Peters is also Professor and Chair of Urology at the Oakland University William Beaumont School of Medicine in Rochester, Michigan. He graduated with honors from the University of Michigan in Ann Arbor and earned his medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio. Dr. Peters subsequently completed his training in surgery and urology at William Beaumont Hospital, where he also completed a fellowship in female urology and urodynamics. A specialist in the treatment of voiding dysfunction and female urology, Dr. Peters is a well-respected clinician, educator, and researcher. He is internationally known for his work on interstitial cystitis, neuromodulation for voiding dysfunction, nerve rerouting surgery to restore voiding in patients with spina bifida, and adult human stem cell injection for stress urinary incontinence. Dr. Peters has published over 100 peer-reviewed articles and book chapters. He has twice won the Society for Urodynamics and Female Urology (SUFU) clinical research award. An active member of many professional organizations, Dr. Peters has served on the Research Council of the American Urological Association. At the 2012 annual meeting of the International Pelvic Pain Society, he was a keynote speaker on the management of chronic pelvic pain. Dr. Peters maintains a private practice in Royal Oak.

About Micron Medical
Micron Medical is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with convenient, safe, minimally invasive, and highly cost-effective urological solutions that are easily incorporated into their daily lives. Micron’s goal is to evolve its patented, cutting-edge platform for neuromodulation to standard of care, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management. www.micronmed.com 

Gil Bao
Micron Medical Corporation

Jeremy Feffer
LifeSci Advisors

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

Primary Logo

Related Links: 
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.